Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to name a new CEO by March 2023

<< Previous

Bullboard Posts

Next >>

Comment by Angler101on Feb 08, 2023 3:57pm

136 Views

Post# 35275425

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Roche to name a new CEO by March 2023

Itntdf.....with all due respect, I don’t think anyone, including notable was suggesting AN was going to walk away for a pittance..... but although AN’s position does look admittedly rose, remember their deal with Oncy included royalty payments, when, instead of doing any deal, they could have just placed a few spies into Oncy’s ranks(they’re probably there already) and simply have stolen the IP anyway.

<< Previous

Bullboard Posts

Next >>

Rick Rule’s election insights: Gold, USD, and Canadian gas